Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MedeFile to market iPHR solutions in Spain
MedeFile has agreed to form a 50/50 JV with a group of senior business and marketing executives in Spain. The JV partners and MedeFile International have agreed to
MedeFile has agreed to form a 50/50 JV with a group of senior business and marketing executives in Spain. The JV partners and MedeFile International have agreed to
The suit is related to an abbreviated new drug application that Par filed with the FDA to market a generic version of DUEXIS tablets. The lawsuit claims infringement
The software, along with a patient portal, has been designed to better administer the clinical management of patient care and streamline internal reporting processes. Connexus provided Burman’s with
The Phase III randomized trial of farletuzumab is designed as a three-armed, double-blinded, controlled study. The study will evaluate farletuzumab at two different dosages in combination with second-line
OMONTYS is the once-monthly erythropoiesis-stimulating agent (ESA) for anemia. The approval was based on a new drug application, which included results from two Phase III studies. The studies
The research will combine expertise in data integration, informatics, genomics and imaging to identify subjects at risk of Alzheimer’s at an early disease stage. The study will be
FDA-approved Bionect is indicated for the management of irritation of the skin as well as first and second degree burns, and is currently being promoted and sold by
ADC Therapeutics was formed with an initial budget of $50m and 10 ADC development programs. The company’s plan will be to seek development and marketing partners after Phase
The $322,000 grant is a supplemental award to expand on promising initial research conducted by ACADIA under an earlier grant from MJFF. The new grant is intended to
Under the agreement, the companies will commercialise Ruconest (recombinant human C1 inhibitor) for the treatment of acute attacks of Hereditary Angioedema (HAE) in the Republic of Korea. Ruconest